Want to see MIRM full AI Analyst Report?
MIRM Stock Chart & Stats
$113.03
-$1.33(-1.16%)
At close: 4:00 PM EDT
$113.03
-$1.33(-1.16%)
Day’s Range― - ―
52-Week Range$50.25 - $130.00
Previous CloseN/A
Volume516.94K
Average Volume (3M)919.61K
Market Cap
$6.56B
Enterprise Value$5.37K
Total Cash (Recent Filing)$386.26M
Total Debt (Recent Filing)$323.78M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 05, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.61
Shares Outstanding60,981,228
10 Day Avg. Volume584,111
30 Day Avg. Volume919,612
Financial Highlights & Ratios
PEG Ratio2.25
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$147.00Price Target Upside30.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-15.63
Revenue Forecast (FY)$674.49M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Raised GuidanceSustained top-line growth and an upward guidance revision reflect durable commercial demand for LIVMARLI and related bile-acid medicines. This expanding revenue base underpins reinvestment capacity, scales the commercial model, and improves the runway for margin conversion as launches and geographies expand.
Strong Commercial Contribution MarginsMid-50% cash contribution margins indicate attractive unit economics and strong product-level profitability. With historically high gross margins, these margins provide structural leverage: as fixed SG&A and R&D normalize, incremental sales should disproportionately flow to operating cash flow and eventual GAAP profitability.
Pipeline And BD Creating Near-term Regulatory CatalystsThe Incyte deal and multiple positive mid-stage readouts broaden Mirum's addressable markets beyond pediatric PFIC into FOP, PSC and HDV. Near-term regulatory catalysts and potential launches diversify revenue sources, de-risk single-product dependence and can materially alter multi-year revenue trajectory if approvals succeed.
Bears Say
Volatile Cash Generation And Near-term Cash BurnMinimal operating cash flow and a TTM swing to materially negative operating and free cash flow indicate funding vulnerability. Durable operations (R&D, launches, and integrations) will require steady cash conversion; until consistent positive operating cash flow arrives, the company remains dependent on external financing.
Increased Leverage And Complex Convertible FinancingLarge, long-dated convertible notes materially changed capital structure and raise leverage and dilution risk. With reported debt-to-equity near ~1.0–1.4, persistent losses would amplify refinancing and covenant risk, limiting flexibility to fund R&D or commercial rollouts without further issuer-friendly financing or dilution.
Very Large Acquisition-related Operating Charge And Elevated Expense BaseA one-time, very large acquisition charge heavily inflated quarterly operating costs and masks underlying operating performance. Elevated R&D and SG&A, plus integration costs, delay GAAP profitability and increase the near-term funding burden, potentially compressing margins while the company scales new assets.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $50.25 and its highest was $130.00 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $6.56B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Aug 05, 2026 which is in 5 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on May 06, 2026. The company reported -$13.43 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$13.065.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -0.73.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 60,981,228 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$13.43 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went down -6.495%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$147.00 (30.05% Upside)
$147.00 (30.05% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 576.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
29.07%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. (MIRM) is a biopharmaceutical company focused on developing and commercializing therapies for rare liver diseases. The company’s core commercial product is LIVMARLI (maralixibat), an oral ileal bile acid transporter (IBAT) inhibitor used to treat cholestatic pruritus in certain pediatric cholestatic liver diseases, and it is also developing CHENODAL (chenodiol) and other pipeline programs aimed at rare hepatology indications.
MIRM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline and BD progress: solid Q1 sales growth (~42.9% YoY), an upward revision to full-year guidance, funded R&D investments, prioritized near-term regulatory catalysts (including a PDUFA on September 26, 2026), and a plan to scale the commercial team. These positives are tempered by a very large, one-time operating expense tied to the Bluejay acquisition that drove an unusually high quarterly operating charge ($761M of $949M), minimal Q1 operating cash flow (~$2M), elevated R&D spend, and remaining data and market-size uncertainties for some pipeline assets (e.g., FOP patient counts and certain subgroup signals in hepatitis delta). Management expects operating cash flow positivity next year and GAAP profitability by 2028, indicating confidence in the business model despite near-term accounting and investment-driven headwinds.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$147.00
▲(30.05% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
PTC Therapeutics
―
Viking Therapeutics
―
Ownership Overview
7.98% Insiders
29.90% Mutual Funds
2.00% Other Institutional Investors
45.22% Public Companies and Individual Investors